Welcome to our dedicated page for HCYT news (Ticker: hcyt), a resource for investors and traders seeking the latest updates and insights on HCYT stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect HCYT's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of HCYT's position in the market.
H-CYTE, Inc. (OTCQB: HCYT) announced significant findings from its clinical study published in the Journal of Regenerative Medicine & Biology Research. The study shows that 23% of COPD patients improved lung function by at least 15% at 3 months and 29% at 12 months post autologous treatment. Additionally, 64% and 67% of participants reported enhanced quality of life at these intervals. The treatment was well-tolerated with no adverse events noted. CEO Robert Greif highlighted the importance of these results in validating H-CYTE's operational strategies.
H-CYTE, Inc. (OTCQB: HCYT) has appointed Robert Greif as the new CEO, effective immediately. Greif brings extensive pharmaceutical experience, having guided over a dozen products from discovery to commercialization. His leadership aims to position H-CYTE as a pioneering biotech company focused on regenerative cellular therapeutics. The transition comes as the company seeks to innovate and expand its clinical research pipeline to address various chronic health conditions. Prior CEO William E. Horne will remain on the board.